Trial Profile
A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Acronyms FIMARO
- Sponsors Boryung Pharmaceutical
- 03 May 2020 Status changed from recruiting to completed.
- 03 May 2020 Results published in the Clinical Therapeutics
- 25 Jul 2017 Planned End Date changed from 1 Apr 2017 to 30 Mar 2018.